Bill
Bill > HR7658
US HR7658
US HR7658To amend the Federal Food, Drug, and Cosmetic Act to reauthorize the Critical Path Public-Private Partnerships.
summary
Introduced
05/03/2022
05/03/2022
In Committee
05/03/2022
05/03/2022
Crossed Over
Passed
Dead
01/03/2023
01/03/2023
Introduced Session
117th Congress
Bill Summary
A BILL To amend the Federal Food, Drug, and Cosmetic Act to reauthorize the Critical Path Public-Private Partnerships.
AI Summary
This bill amends the Federal Food, Drug, and Cosmetic Act to reauthorize the Critical Path Public-Private Partnerships, which is a program that facilitates collaboration between the Food and Drug Administration (FDA) and private entities to support the development of new medical products. Specifically, the bill increases the authorized funding for the program from $6 million per year for fiscal years 2018 through 2022 to $10 million per year for fiscal years 2023 through 2027.
Committee Categories
Business and Industry
Sponsors (2)
Last Action
Referred to the House Committee on Energy and Commerce. (on 05/03/2022)
Official Document
bill text
bill summary
Loading...
bill summary
Loading...
bill summary
| Document Type | Source Location |
|---|---|
| State Bill Page | https://www.congress.gov/bill/117th-congress/house-bill/7658/all-info |
| BillText | https://www.congress.gov/117/bills/hr7658/BILLS-117hr7658ih.pdf |
| Bill | https://www.congress.gov/117/bills/hr7658/BILLS-117hr7658ih.pdf.pdf |
Loading...